Inhibitor Therapeutics (INTI) Tax Provisions (2018 - 2019)
Inhibitor Therapeutics' (INTI) quarterly Tax Provisions came in at $7.5 million in Q4 2019, up 9.39% on a YoY basis from $6.9 million in Q4 2018, and up 9.39% quarter-over-quarter from $6.9 million in Q4 2018.
Powered by 
Analysis
Inhibitor Therapeutics (INTI) Tax Provisions (2018 - 2019) Analysis & Trends
Inhibitor Therapeutics (INTI) has reported Tax Provisions for 2 consecutive years, with $7.5 million the latest figure, recorded in Q4 2019.
- For the quarter ending Q4 2019, Tax Provisions rose 9.39% year-over-year to $7.5 million; the trailing twelve-month figure through Dec 2019 stood at $7.5 million (up 9.39% YoY), and the FY2023 full-year result was -$635488.0, down 125.28% from the prior year.
- Tax Provisions advanced to $7.5 million in Q4 2019 per INTI's latest filing, from $6.9 million in the prior quarter.
- Across five years, Tax Provisions topped out at $7.5 million in Q4 2019 and bottomed at $6.9 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -1.01 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -407.00 Mn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -524.23 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 165.91 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 39.70 Mn |
| 10 | Inhibitor Therapeutics | 12.17 Mn | 12.17 Mn | - | - |